Trial Profile

A Single Arm, Single Stage Phase II Trial of GSK1120212 and GSK2141795 in Persistent or Recurrent Cervical Cancer

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 25 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trametinib (Primary) ; Uprosertib (Primary)
Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

20 May 2019 Results to evaluate the inhibition of PI3K and RAS signaling by combining the MEK inhibitor trametinib and the AKT inhibitor GSK2141795 in recurrent cervical cancer are published in the Gynecologic Oncology.
16 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017.
05 Apr 2017 Results analysing clinical activity and safety of trametinib [GSK-1120212] + GSK2141795 in patients with recurrent or metastatic cervical cancer, presented at the 108th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com